| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5886184 | ORGANON | Finasteride processes |
Nov, 2012
(11 years ago) | |
| US5547957 | ORGANON | Method of treating androgenic alopecia with 5-α reductase inhibitors |
Oct, 2013
(10 years ago) | |
| US5571817 | ORGANON | Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones] |
Nov, 2013
(10 years ago) | |
Propecia is owned by Organon.
Propecia contains Finasteride.
Propecia has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Propecia are:
- US5886184
- US5547957
- US5571817
Propecia was authorised for market use on 19 December, 1997.
Propecia is available in tablet;oral dosage forms.
Propecia can be used as treating male pattern baldness with 0.05 to 3.0mg/day, treatment of androgenic alopecia by oral administration drug substance.
The generics of Propecia are possible to be released after 05 November, 2013.
Drugs and Companies using FINASTERIDE ingredient
Market Authorisation Date: 19 December, 1997
Treatment: Treating male pattern baldness with 0.05 to 3.0mg/day; Treatment of androgenic alopecia by oral administration drug substance
Dosage: TABLET;ORAL
PROPECIA family patents
